SenzaGen increases its presence in the US via a license agreement with MB Research Labs
SenzaGen has signed a license agreement with the contract research organization (CRO), MB Research Labs, which is a leader in GLP in vitro toxicological testing in the United States. The agreement gives MB Research Labs the right to market and sell SenzaGen’s animal-free GARD™ test platform worldwide and also further strengthening SenzaGen’s presence in the US market.MB Research is a prominent proponent of modern cell- and mechanistic-based solutions and has a market-leading position in in vitro toxicological testing in the US for the cosmetic, consumer product and industrial chemical